Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

J&J buys Synthes for $21.7bn

Executive Summary

Johnson & Johnson has made its largest acquisition to date via the purchase of public orthopedic device manufacturer Synthes Inc. for $21.7bn (CHF18.6bn). Shareholders will receive $182 per share (a 30% premium), of which $63.57 will be paid in cash and $118.07 in J&J common stock (almost 2 shares) as long as J&J’s shares stay between $60.20 and $69.26 during the 10-day trading period leading up to the close of the transaction.
Deal Industry
  • Biotechnology
  • Medical Devices
  • Medical Devices
    • Biomaterials
    • Implantable Devices
    • Surgical Equipment & Devices
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Cash
    • Payment Includes Stock

Related Companies